GNOS Genosis

RNS Number:9937E
Genosis PLC
22 June 2006


For immediate release                                               22 June 2006





                                  GENOSIS PLC

                       Statement re: Share price movement



The Board of Genosis PLC ("Genosis" or the "Company"; RIC code - GNOS), a UK
company focusing on consumer products for reproductive health, notes the recent
fall in the Company's share price. The Board knows of no reason for this fall
and reiterates the update given at its Annual General Meeting on 8 June 2006.



For further details, please contact:
                                                            Today on:
Genosis PLC                     Paul Bateman, CEO           +44 (0)20 7466 5000
Buchanan Communications         Lisa Baderoon / 
                                Rebecca Skye Dietrich       +44 (0)20 7466 5000
Evolution Securities            Tim Worlledge / 
                                Gina Gibson                 +44 (0)20 7071 4300



NOTES TO EDITORS

Genosis is a consumer products company focused on reproductive health. Genosis'
first product Fertell(R), an at-home fertility testing kit for men and women,
went on sale in the UK in January 2006.  The key benefits of Fertell(R) are that
it allows men and women to assess their fertility status in the privacy of their
own home and that, the earlier couples can identify whether a problem exists,
the earlier they can seek treatment and the more likely they are to conceive.

Fertell(R) was designed and developed by Genosis and is the first and currently
the only OTC product on the high street that allows couples to accurately test
both male and female fertility quickly and simply in the privacy of their own
home. Genosis' product Fertell(R) makes the breakthrough of taking accepted
technology from the laboratory into easy to use fertility testing devices for
testing at home.

Fertell(R) is easy to use. The woman's test is used in a similar way to a
pregnancy test but, unlike any other test that is available for use at home, it
assesses the quality of the egg she releases. For the male test, the man has to
produce a sample, push a button and twist a switch and, in just over an hour,
the test will show him if he has enough motile sperm that can swim to reach an
egg (based on WHO standards). Fertell(R) has been through clinical trials in the
UK and the US and has been shown to be more than 95% accurate when compared with
standard laboratory tests run in fertility clinics. Fertell(R) has been cleared
for sale in the US by the FDA and has received CE marking for sale in Europe.

The Company's first retail distribution agreement is with Boots, the UK's
biggest healthcare retailer with more than 1,200 stores nationwide. The Boots
Distribution Agreement is exclusive for the UK until 2008. Boots sells Fertell
through its high street branches in the UK and the Republic of Ireland and over
the internet.  The Fertell kit is also available through Genosis' own website,
www.fertell.co.uk.

The potential market for Fertell(R) is estimated to be in excess of US $500
million per annum (Western Europe, North America and Japan). There are in excess
of 500 million couples of reproductive age worldwide, and approximately 1 in 7
or c80 million have problems conceiving. There is a significant increase in the
industrialised world in the number of women deferring childbearing until after
30. This has a marked effect on fertility. Although male factor infertility is
the single most common cause of infertility, the key prognostic indicator of a
couple's fertility is the age of the female partner, with fertility rates, upon
treatments such as IVF, halving between the ages of 30 and 38. In the UK,
couples most frequently turn to their medical providers for assistance, but
typically are advised to wait and try to conceive for a further period of up to
12 months before returning for tests and treatment.
www.genosis.com                                                www.fertell.co.uk





                                  - E N D S -




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

SPMUAVORNWRNUUR

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Giu 2023 a Giu 2024